On 13th May, Rhythm’s Genetype scientists published their impressive colorectal cancer risk assessment research in peer reviewed medical research journal Plos One. 400,000 bio banked UK patient samples were analysed.
The findings are significant - “Using our risk prediction models, we can identify individuals who are at substantially increased risk, even if they do not have a first-degree family history. Previously, these individuals would have been missed and not able to avail themselves of additional screening appropriate for people at increased risk.”
Full research article- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0321641
Rhythm’s technologies (Genetype and Colostat) do appear to place it nicely at the forefront of inexpensive, simple, plasma and saliva based colorectal cancer risk population screening. And word is getting out!
RHY Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)